Brief: Ys Biopharma - Phase 3 Clinical Trial Planned To Commence Later In 2023
01/06/2023 13:47
June 1 (Reuters) - YS Biopharma Co Ltd YS.O :
* YS BIOPHARMA'S PIKA RABIES VACCINE RECEIVES PHASE 3
CLINICAL
TRIAL APPROVAL FROM PHILIPPINES FDA
* YS BIOPHARMA - PHASE 3 CLINICAL TRIAL PLANNED TO COMMENCE
LATER
IN 2023
Source text for Eikon: ID:nPn1xKZCfa
Further company coverage: YS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LakeShore Biopharma Co
See all newsBrief: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
Brief: LakeShore Biopharma Appoints Advisors to Special Committee Reviewing Takeover Bid
Brief: Lakeshore Biopharma Announces Receipt Of A Preliminary Non-Binding Proposal To Acquire The Company
Brief: Lakeshore Biopharma Expects 2026 Revenue To Be Between RMB550 Million And RMB650 Million
Brief: Lakeshore Biopharma Announces Us$15 Million Private Placement Financing